The global biotechnology sector is facing increasing generic competition. Meanwhile, patent expiration of a number of blockbuster drugs may lead to increased M&A activity in the sector as large pharmaceutical companies look to acquire smaller biotech firms that are developing blockbuster drugs. For smaller biotech companies, acquisitions or collaborations with large, cash-rich pharmaceutical companies would make strategic sense as this would give them access to capital and a large distribution network. Innovation will remain key for biotechnology companies such as Sequenom Inc. (NASDAQ:SQNM), Life Technologies Corp. (NASDAQ:LIFE), and Illumina Inc. (NASDAQ:ILMN) at a time of increasing generic competition and regulatory changes. Street-Wire.com has added SQNM, LIFE and ILMN this morning to their Daily Rating Watch List. Rating can mean a number of things for investors and we encourage all shareholders to sign up to speak to a member of our research team today at
Sequenom Sees Remarkable Progress in 2012
Last month, Sequenom announced preliminary 2012 operational highlights. According to Harry F. Hixson, Jr., Ph.D., Chairman and CEO of Sequenom, 2012 was a year of remarkable progress for the company. Hixson noted that the rapid adoption of the Sequenom CMM's MaterniT21 PLUS by the OB/GYN physician community far exceeded the company's internal goal and estimates of industry analysts. SQNM has come under our radar and we have issued a new rating for this equity. Sign up for free below to find out more.
Sequenom said that its total revenue for 2012 grew approximately 59% on a year-over-year basis to $89 million.
On Monday, SQNM shares ended 0.21% lower at $4.69 on volume of 2.93 million. Despite the drop on Monday, technical indicators for SQNM are currently giving bullish signals. A strong bullish trend will be established if the stock breaks through $4.80 resistance level.
Life Technologies Receives FDA Clearance for 3500 Dx Genetic Analyzers and SeCore(R) HLA Typing Kits
On Monday, Life Technologies announced the receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for its 3500 Dx Genetic Analyzers and SeCore(R) HLA typing kits. LIFE has met 8 out of 10 characteristics we look for when rating an equity. Register now for free below to find out more.
Meanwhile, Life Technologies last week said that its Board of Directors is continuing with a strategic review. The company said that its Board has made no decisions so far and all strategic options, including a possible sale, are still open. At around the same time period, Life Technologies also reported its financial results for the fourth quarter ended December 31, 2012, posting non-GAAP revenue of $999 million, up 3% over the comparable period of the previous year.
Life Technologies shares fell marginally on Monday, ending the day 0.14% lower at $62.78. LIFE shares currently have strong support at around $62. The stock has been facing resistance at around $65. The stock's MACD recently moved below the signal line, which is a bearish signal.
Illumina Posts Record Results
Late last month, Illumina reported record financial results for the fourth quarter and full-year 2012. The company's revenue for the quarter rose 24% to $309 million. Non-GAAP net income for the quarter was $57 million, or $0.42 per share, up from $44 million, or $0.35 per share reported for the same period in the previous year. ILMN has met 8 out of 10 characteristics we look for when rating an equity. Sign up for free below to find out more.
Illumina shares ended 1.24% lower at $50.25 on Monday. ILMN shares have been trading sideways over the past few weeks. The stock has been struggling to break through $52 resistance level. It has support at around $50. A bullish trend will be established if ILMN breaks through $52.
Disclaimer:SWire News Media is not a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security. A third party, www.street-wire.com has paid SWire News Media four hundred and fifty dollars for the publication of this news release. Neither SWire News Media, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release.
For full disclaimer visit: http://www.street-wire.com/disclaimer.html
Anthony K. Merchant